echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Zhejiang Pharmaceutical ARX305 obtains notification of acceptance of drug clinical trial application

    Zhejiang Pharmaceutical ARX305 obtains notification of acceptance of drug clinical trial application

    • Last Update: 2021-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 22, Zhejiang Medicine issued an announcement stating that its subsidiary, Zhejiang Xinma Biomedicine Co.


    Recombinant humanized anti-CD70 monoclonal antibody-AS269 conjugate (ARX305) for injection is a new generation of monoclonal antibody conjugate drug developed by the company on October 22, 2019, which signed the "Cooperative Development and License Agreement" with Ambrx in the United States.


    As of November 30, 2021, the company's ARX305 project has invested a total of 65.


    CD70 is a member of the tumor necrosis factor receptor (TNFR) superfamily.


    The CD70 monoclonal antibodies that have been or are being developed abroad include MDX1411, ARGX-110 and SEA-CD70, and ADCs include SGN-75, SGN-CD70A, MDX-1203 and AMG172.


    At present, there is no marketed drug targeting CD70 at home and abroad


    Cancer is one of the most important public health problems in the 21st century, with high morbidity and mortality rates worldwide


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.